← Holders
Kynam Capital Management, LP
What Kynam Capital Management, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1907884 · Filed Nov 16, 2026
- Positions
- 34
- Reported value
- $1.8B
- Opened
- 4
- Closed
- 2
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$1.3B35 positions
- Dec 31, 2025$1.6B37 positions
- Mar 31, 2026$1.6B39 positions
- Jun 30, 2026$1.8B32 positions
- Sep 30, 2026$1.8B34 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
LEGNLegend Biotech Corp | 9.2M | +205.0% | $182.1M | 10.1% |
CLDXCelldex Therapeutics, Inc. | 5.1M | −4.8% | $164.2M | 9.1% |
SNDXSyndax Pharmaceuticals Inc | 8.2M | +1.2% | $153.2M | 8.5% |
PCVXVaxcyte, Inc. | 2.6M | −10.8% | $148.4M | 8.2% |
VRDNViridian Therapeutics, Inc. | 6.1M | −4.7% | $126.6M | 7% |
COGTCogent Biosciences, Inc. | 3.8M | +3.4% | $121.4M | 6.7% |
TVTXTravere Therapeutics, Inc. | 2M | ±0% | $117.8M | 6.5% |
URGNUroGen Pharma Ltd. | 2.4M | ±0% | $98.9M | 5.5% |
VERAVera Therapeutics, Inc. | 3M | +3.8% | $96.9M | 5.4% |
BEAMBeam Therapeutics Inc. | 3.9M | +38.5% | $96.2M | 5.3% |
CTMXCytomX Therapeutics, Inc. | 21.1M | −2.6% | $57.5M | 3.2% |
MBXMBX Biosciences, Inc. | 934.8K | ±0% | $54.8M | 3% |
SMMTSummit Therapeutics Inc. | 3M | +150.0% | $50.7M | 2.8% |
RLAYRelay Therapeutics, Inc. | 2.8M | −16.6% | $49.7M | 2.7% |
CGEMCullinan Therapeutics, Inc. | 3.1M | ±0% | $47.8M | 2.6% |
IMCRImmunocore Holdings plc | 1.4M | ±0% | $41.6M | 2.3% |
NRIXNurix Therapeutics, Inc. | 1.2M | ±0% | $28.3M | 1.6% |
PHVSPharvaris N.V. | 824.8K | +24.6% | $26.2M | 1.4% |
BNRBurning Rock Biotech Ltd | 1.2M | ±0% | $21.8M | 1.2% |
BCRXBiocryst Pharmaceuticals Inc | 2.5M | ±0% | $21M | 1.2% |
SRZNSurrozen, Inc. | 486.3K | New | $15.6M | 0.9% |
STROSutro Biopharma, Inc. | 872.6K | ±0% | $14.1M | 0.8% |
XENEXenon Pharmaceuticals Inc. | 280K | New | $10.4M | 0.6% |
EVMNEvommune, Inc. | 1.2M | New | $9.9M | 0.5% |
PRLDPrelude Therapeutics Inc | 2.3M | −4.3% | $9M | 0.5% |
GERNGeron Corp | 6.8M | ±0% | $8.4M | 0.5% |
PBLSParabilis Medicines, Inc. | 250K | ±0% | $8.1M | 0.4% |
ALECAlector, Inc. | 4.3M | +13.1% | $8M | 0.4% |
AMRNAmarin Corp Plcuk | 533K | ±0% | $6.9M | 0.4% |
HROWHarrow, Inc. | 124.7K | New | $3.8M | 0.2% |
CRBUCaribou Biosciences, Inc. | 2.5M | ±0% | $3.2M | 0.2% |
PRQRProQR Therapeutics N.V. | 1.6M | ±0% | $2.6M | 0.1% |
ENGNenGene Therapeutics Inc. | 457.9K | ±0% | $915.7K | 0.1% |
TRAWTraws Pharma, Inc. | 84.4K | ±0% | $50.1K | 0.1% |